202 related articles for article (PubMed ID: 36206317)
41. HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer.
Zivanovic O; Abramian A; Kullmann M; Fuhrmann C; Coch C; Hoeller T; Ruehs H; Keyver-Paik MD; Rudlowski C; Weber S; Kiefer N; Poelcher ML; Thiesler T; Rostamzadeh B; Mallmann M; Schaefer N; Permantier M; Latten S; Kalff J; Thomale J; Jaehde U; Kuhn WC
Int J Cancer; 2015 Feb; 136(3):699-708. PubMed ID: 24895230
[TBL] [Abstract][Full Text] [Related]
42. Loss of RBMS3 Confers Platinum Resistance in Epithelial Ovarian Cancer via Activation of miR-126-5p/β-catenin/CBP signaling.
Wu G; Cao L; Zhu J; Tan Z; Tang M; Li Z; Hu Y; Yu R; Zhang S; Song L; Li J
Clin Cancer Res; 2019 Feb; 25(3):1022-1035. PubMed ID: 30279231
[TBL] [Abstract][Full Text] [Related]
43. Hypermethylation of mismatch repair gene hMSH2 associates with platinum-resistant disease in epithelial ovarian cancer.
Tian H; Yan L; Xiao-Fei L; Hai-Yan S; Juan C; Shan K
Clin Epigenetics; 2019 Oct; 11(1):153. PubMed ID: 31666131
[TBL] [Abstract][Full Text] [Related]
44. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
[TBL] [Abstract][Full Text] [Related]
45. Suppression of REV7 enhances cisplatin sensitivity in ovarian clear cell carcinoma cells.
Niimi K; Murakumo Y; Watanabe N; Kato T; Mii S; Enomoto A; Asai M; Asai N; Yamamoto E; Kajiyama H; Shibata K; Kikkawa F; Takahashi M
Cancer Sci; 2014 May; 105(5):545-52. PubMed ID: 24597627
[TBL] [Abstract][Full Text] [Related]
46. Acylglycerol kinase promotes ovarian cancer progression and regulates mitochondria function by interacting with ribosomal protein L39.
Sun F; Wei Y; Liu Z; Jie Q; Yang X; Long P; Wang J; Xiong Y; Li Q; Quan S; Ma Y
J Exp Clin Cancer Res; 2022 Aug; 41(1):238. PubMed ID: 35934718
[TBL] [Abstract][Full Text] [Related]
47. Cytoreductive Surgery (CRS) Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Platinum-Sensitive Recurrence Epithelial Ovarian Cancer With HRR Mutation: A Phase III Randomized Clinical Trial.
Qi Y; Zhang Y; Shi Y; Yao S; Dai M; Cai H
Technol Cancer Res Treat; 2022; 21():15330338221104565. PubMed ID: 35929135
[No Abstract] [Full Text] [Related]
48. CXCR4 and RIF1 overexpression induces resistance of epithelial ovarian cancer to cisplatin-based chemotherapy.
Sad LMAE; Mohamed DA; Elanwar NM; Elkady A
J Cancer Res Ther; 2021; 17(6):1454-1461. PubMed ID: 34916377
[TBL] [Abstract][Full Text] [Related]
49. The effect of different combinations of antibiotic cocktails on mice and selection of animal models for further microbiota research.
Xu J; Xu HM; Peng Y; Zhao C; Zhao HL; Huang W; Huang HL; He J; Du YL; Zhou YJ; Zhou YL; Nie YQ
Appl Microbiol Biotechnol; 2021 Feb; 105(4):1669-1681. PubMed ID: 33511441
[TBL] [Abstract][Full Text] [Related]
50. Methoxyphenyl chalcone sensitizes aggressive epithelial cancer to cisplatin through apoptosis induction and cancer stem cell eradication.
Su YK; Huang WC; Lee WH; Bamodu OA; Zucha MA; Astuti I; Suwito H; Yeh CT; Lin CM
Tumour Biol; 2017 May; 39(5):1010428317691689. PubMed ID: 28466786
[TBL] [Abstract][Full Text] [Related]
51. Manipulation of Gut Microbiota Influences Immune Responses, Axon Preservation, and Motor Disability in a Model of Progressive Multiple Sclerosis.
Mestre L; Carrillo-Salinas FJ; Mecha M; Feliú A; Espejo C; Álvarez-Cermeño JC; Villar LM; Guaza C
Front Immunol; 2019; 10():1374. PubMed ID: 31258540
[TBL] [Abstract][Full Text] [Related]
52. Chemosensitizing effects of metformin on cisplatin- and paclitaxel-resistant ovarian cancer cell lines.
Dos Santos Guimarães I; Ladislau-Magescky T; Tessarollo NG; Dos Santos DZ; Gimba ERP; Sternberg C; Silva IV; Rangel LBA
Pharmacol Rep; 2018 Jun; 70(3):409-417. PubMed ID: 29627688
[TBL] [Abstract][Full Text] [Related]
53. The PAPSS1 gene is a modulator of response to cisplatin by regulating estrogen receptor alpha signaling activity in ovarian cancer cells.
Sun L; Ji WX; Li Y; Li ZL; Duan CC; Xia BR; Xiao L
J Ovarian Res; 2023 Sep; 16(1):187. PubMed ID: 37684671
[TBL] [Abstract][Full Text] [Related]
54. Intestinal microbiota regulates anti-tumor effect of disulfiram combined with Cu
Hu H; Cui L; Lu J; Wei K; Wei J; Li S; Zou C; Chen T
Cancer Med; 2020 Sep; 9(18):6791-6801. PubMed ID: 32750218
[TBL] [Abstract][Full Text] [Related]
55. CDK7 is a reliable prognostic factor and novel therapeutic target in epithelial ovarian cancer.
Kim J; Cho YJ; Ryu JY; Hwang I; Han HD; Ahn HJ; Kim WY; Cho H; Chung JY; Hewitt SM; Kim JH; Kim BG; Bae DS; Choi CH; Lee JW
Gynecol Oncol; 2020 Jan; 156(1):211-221. PubMed ID: 31776040
[TBL] [Abstract][Full Text] [Related]
56. Effect of platinum sensitivity on the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in recurrent epithelial ovarian cancer.
Costales AB; Chambers L; Chichura A; Rose PG; Mahdi H; Michener CM; Yao M; Debernardo R
J Gynecol Obstet Hum Reprod; 2021 May; 50(5):101844. PubMed ID: 32590110
[TBL] [Abstract][Full Text] [Related]
57. Role of common ERCC1 polymorphisms in cisplatin-resistant epithelial ovarian cancer patients: A study in Chinese cohort.
Bao Y; Yang B; Zhao J; Shen S; Gao J
Int J Immunogenet; 2020 Oct; 47(5):443-453. PubMed ID: 32173978
[TBL] [Abstract][Full Text] [Related]
58. Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer.
Mercier PL; Bachvarova M; Plante M; Gregoire J; Renaud MC; Ghani K; Têtu B; Bairati I; Bachvarov D
Mol Oncol; 2011 Oct; 5(5):438-53. PubMed ID: 21856257
[TBL] [Abstract][Full Text] [Related]
59. Evaluation of hyperbaric oxygen as a chemosensitizer in the treatment of epithelial ovarian cancer in xenografts in mice.
Alagoz T; Buller RE; Anderson B; Terrell KL; Squatrito RC; Niemann TH; Tatman DJ; Jebson P
Cancer; 1995 May; 75(9):2313-22. PubMed ID: 7536123
[TBL] [Abstract][Full Text] [Related]
60. Association of expression of XIAP-associated factor 1 (XAF1) with clinicopathologic factors, overall survival, microvessel density and cisplatin-resistance in ovarian cancer.
Wang Y; Mao H; Hao Q; Wang Y; Yang Y; Shen L; Huang S; Liu P
Regul Pept; 2012 Oct; 178(1-3):36-42. PubMed ID: 22759793
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
